EMA and ECDC recommendations on heterologous vaccination courses against COVID-19 Share
News 07/12/2021
‘Mix-and-match’ approach can be used for both initial courses and boosters
Laduree
Posts
-
-
Thank you shorts for the dips. Load up more shares
-
Futures are still green.
-
We all know Covid vaccines are not 100% efficacy. About 10% population will still get affected after fully vaccination. However, vaccination protects those 10% from being killed by the virus.
-
The index futures are still green. No panics about Pfizer’s statement on ineffective vaccines to omicron today. Who panicky sold yesterday and last week must have regretted today. Learn the lessons.
-
Travel bans are still there to block and delay omicron. The world’s major problem is still Delta for the long run.
-
Any big dumps after hours were the borrowed shares lended by your brokers to shorters
-
Any big dumps after hours were the borrowed shares lended by your brokers to shorters
-
Thank you shorts. Bought after hour dips.
-
European bulls and whales are buying NVAX
-
Retailer shorters like Lauren Murielle and RexMan are fighting with NVAX Whales
-
Parabolic run lol
-
Emer Cooke is an Irish pharmacist and Executive Director of the European Medicines Agency since November 2020. She is also the chairperson at the International Coalition of Medicines Regulatory Authorities.
-
Novavax COVID-19 vaccine could be approved very soon, says EMA chief
Reuters
December 7, 20216:19 AM PSTLast Updated an hour ago
BRUSSELS, Dec 7 (Reuters) - The head of the European Medicines Agency (EMA) on Tuesday said that it could soon approve the COVID-19 vaccine developed by U.S. biotech company Novavax (NVAX.O)."The vaccine from Novavax could be authorised in the very near future," Emma Cooke told EU health ministers during a public session of a meeting in Brussels.
-
Frankfurt ticket NVV1.F
Munich ticket NVV1.MU -
Manufacturing issue should have been cleared by EMA certificate on 11/11/2021 which will be valid for 3 years
The manufacturer :NOVAVAX CZ a.s.
CERTIFICATE NUMBER :sukls299102/2021(1) The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.
(2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.
(3) These requirements fulfil the GMP recommendations of WHO. -
Marco Cavaleri is Head of Office, Biological Health Threats and vaccines strategy. He is the Chair of EMA COVID Task force and responsible for EMA activities for emergent pathogens, vaccines, and AMR.
Page12-13
-
Although Biden Fauci said it seemed that Omicron symptoms could be mild so far but they haven’t dared to lift South African travel ban!!! Why so? Because its super contagious and in all news those infected peoples tested positive are already fully vaccinated.
-
The GMP compliance manufacturer certificate is valid for three years.
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX